US regulators give limited approval to cholesterol drug

July 25, 2015

US regulators on Friday approved a new cholesterol drug called Praluent, made by Sanofi and Regeneron, for people with certain genetic risk factors for heart disease.

The injectable drug is the first of its kind to gain approval on the US market, and offers an alternative to popular pill-based statins.

However, the US Food and Drug Administration approved it only for adults with an inherited condition that predisposes them to high cholesterol and raises the risk of heart attack and stroke.

"Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol," the FDA said in a statement.

HeFH is an inherited condition that causes high levels of the bad kind of cholesterol, known as low-density lipoprotein (LDL) .

Known also as alirocumab, the treatment is part of a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.

These drugs block the PCSK9 gene in the liver, which results in plummeting levels of LDL.

Explore further: US experts urge approval of another new cholesterol drug (Update)

Related Stories

US experts urge approval of another new cholesterol drug (Update)

June 10, 2015
US experts urged regulators Wednesday to approve a second new anti-cholesterol drug, a day after recommending they bring to market the first in a new class of medications to lower the risk of heart attack.

FDA weighs approval of first-in-class cholesterol drug

June 5, 2015
Federal health regulators said Friday that a highly-anticipated, experimental drug from Sanofi lowers bad cholesterol more than older drugs. But officials have questions about whether to approve the drug based on that measure ...

FDA panel backs first-in-class cholesterol drug

June 9, 2015
Federal health advisers on Tuesday recommended approval for a highly-anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with the caveat that more data is needed about its long-term ability to reduce ...

FDA panel backs Amgen cholesterol drug for some patients (Update)

June 10, 2015
Federal health advisers said Wednesday that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance.

Europe approves Amgen's first-in-class cholesterol drug

July 21, 2015
Amgen on Tuesday received European approval for its first-of-a-kind cholesterol drug that lowers levels of the artery-clogging substance more than older drugs that have been prescribed for decades.

New class of cholesterol drug proves safe and effective for patients with dyslipidemia

April 27, 2015
Treatment with PCSK9 antibodies reduces mortality and produces profound reductions in LDL-cholesterol and lipoprotein in patients with dyslipidemia. The results of this systematic review and meta-analysis are being published ...

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.